Sanofi Comments on Medivation's Rejection of Proposal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/4/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Medivation (MDVN) PT Raised to $63 at Credit Suisse on M&A Valuation
May 3, 2016 7:27 AM EDTCredit Suisse analyst Kenneth MacKay raised his price target on Medivation (NASDAQ: MDVN) to $63.00 (from $49.00) as he moves to a M&A valuation. The firm maintained an Outperform rating.
MacKay continues to see Sanofi's $52.50/share offer as significantly undervaluing the pipeline and continue to... More
Stifel Raises Medivation Inc (MDVN) PT to $66 with Company In Play
May 2, 2016 7:19 AM EDTStifel analyst, Thomas Shrader, tries to sort through the buyout hype surrounding Medivation (NASDAQ: MDVN) in a note this morning. Recent news reports make it pretty clear Medivation is in play but like many biotechnology stories the value of the company is based on many assumptions. His takeaway is that a fair price would be $66 and possibly as high as $85... More
